



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

| APPLICATION NO. | FILING DATE | FIRST NAMED INVENTOR | ATTORNEY DOCKET NO. | CONFIRMATION NO. |
|---|-------------|----------------------|---------------------|------------------|
| 10/791,635 | 03/02/2004 | Joseph Rock | US010382A | 3051 |
| 28159 | 7590 | 08/07/2007 | EXAMINER | |
| PHILIPS MEDICAL SYSTEMS | | | PATEL, NATASHA | |
| PHILIPS INTELLECTUAL PROPERTY & STANDARDS | | | ART UNIT | PAPER NUMBER |
| P.O. BOX 3003 | | | 3766 | |
| 22100 BOTHELL EVERETT HIGHWAY | | | MAIL DATE | |
| BOTHELL, WA 98041-3003 | | | 08/07/2007 | |
| | | | DELIVERY MODE | |
| | | | PAPER | |

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

| Office Action Summary | Application No. | Applicant(s) |
|------------------------------|------------------------|---------------------|
| | 10/791,635 | ROCK ET AL. |
| | Examiner | Art Unit |
| | Natasha N. Patel | 3766 |

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

1) Responsive to communication(s) filed on RCE filed 5/1/07.

2a) This action is **FINAL**. 2b) This action is non-final.

3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

4) Claim(s) 1-3,5,6,9,10,12-14 and 16 is/are pending in the application.
4a) Of the above claim(s) _____ is/are withdrawn from consideration.

5) Claim(s) _____ is/are allowed.

6) Claim(s) 1-3,5,6,9,10,12-14 and 16 is/are rejected.

7) Claim(s) _____ is/are objected to.

8) Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

9) The specification is objected to by the Examiner.

10) The drawing(s) filed on 02 March 2004 is/are: a) accepted or b) objected to by the Examiner.

Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).

Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).

11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
a) All b) Some * c) None of:
1. Certified copies of the priority documents have been received.
2. Certified copies of the priority documents have been received in Application No. _____.
3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

1) Notice of References Cited (PTO-892)
2) Notice of Draftsperson's Patent Drawing Review (PTO-948)
3) Information Disclosure Statement(s) (PTO/SB/08)
Paper No(s)/Mail Date _____.
4) Interview Summary (PTO-413)
Paper No(s)/Mail Date _____.
5) Notice of Informal Patent Application
6) Other: _____.

DETAILED ACTION

The RCE filed on 5/1/2007 has been received and considered. By this RCE, Claims 4, 7-8, 11, 15, and 17-25 have been cancelled, Claims 1, 6, and 16 have been amended, and no claims have been added. Thus, Claims 1-3, 5-6, 9-10, 12-14, and 16 are now pending in the application.

Response to Arguments

1. Applicant's arguments with respect to claims 1-6, 9-14, and 16 have been considered but are moot in view of the new ground(s) of rejection. Bilof et al. (US Patent 5,191,885) is still being relied upon since Applicant's arguments are not persuasive. Examiner believes that the sharp corners and seams, which the Applicant speaks of, would be covered and therefore become a non-issue when a sheath is in place. Furthermore, Pless is still being relied upon since Claim 6 relates to the stimulation aspect of the probe and not the imaging aspect. Since Bilof and Vesely already provide imaging capability, the stimulation would not be provided blindly. Pless is simply being provided for the teachings of the advantages that balloons offer in making the stimulation more efficient. Finally, Crowley is also still being relied upon for its teaching of an acoustically transparent sheet and not the fitting of the sheet on the probe.

Claim Rejections - 35 USC § 103

2. The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the

Art Unit: 3766

invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

3. Claims 1-3, 5, 9, 12-14, and 16 are rejected under 35 U.S.C. 103(a) as being unpatentable over Bilof et al. (US Patent 5,191,885) in view of Vesely (US Patent 5,830,144).

4. Regarding Claim 1, Bilof discloses a system providing cardiac stimulation in combination with an endoscopic imaging probe (see col. 1, lines 50-51), comprising: a cardiac stimulation electrical conductor (see conducting member 36a; col. 3, lines 39-40); and an electrical cable (see cable 44; col. 3, lines 54-56), attached to the cardiac stimulation electrical conductor (see Figure 6), and adapted to be connected to an external defibrillator (see external defibrillator 50 or 102; col. 3, lines 56-66 and col. 6, lines 22-29). Bilof discloses a disposable, removable protective sheet affixed to the endoscopic imaging probe (see sheet member 76; col. 5, lines 33-44), wherein the cardiac stimulation electrical conductor (see conductor 66a or 36a) are integrated with the protective sheet (see Figure 8). Furthermore, since protective sheet 76 only extends up to plastic extension member 40, cable 44 is not protected by the sheet (see Figure 6). However, Bilof does not disclose that the protective sheet forms a sheath, which by definition requires some type of enveloping structure or enclosing cover. Nevertheless, sheaths are well known in the medical lead art. For example, Vesley discloses a disposable, removable sheath of a flexible membrane material (see tracking data sheath 20, 20', 100; col. 2, lines 56-60 and 65-67) sized to slidably cover (see col. 5, lines 13-15) the transesophageal portion of the endoscopic imaging probe (see col. 1, lines 27-30) and permit transesophageal ultrasonic imaging by the endoscopic imaging

Art Unit: 3766

probe within the sheath (see col. 4, lines 9-12). It would have been obvious to one of ordinary skill in the art at the time of the invention to use Vesely's tracking data sheath with Bilof's invention because Vesely teaches that doing so allows for *quickly* and easily modifying an instrument to include tracking capabilities that are necessary to provide therapy in a specific location (see col. 2, lines 50-53).

5. Regarding Claim 2, Bilof discloses a connector receiving the cable and adapted to connect the cable to the external defibrillator (see switch 46; col. 3, lines 56-63 and Figure 6); and a transthoracic pad connected to the external defibrillator for the cardiac stimulation (see col. 6, lines 28-35; Figure 11).

6. Regarding Claim 3, Bilof discloses a second cardiac stimulation electrical conductor (see conducting member 36b or 66b) located on the sheath, wherein an electrical path for cardiac stimulation is provided between the first and second conductors (see electrical connector 40; col. 3, lines 46-54).

7. Regarding Claim 5, Bilof discloses that the probe is insertable through a mouth into an esophagus of a patient (see col. 4, lines 24-25). Bilof also discloses an insulation type coating (see col. 5, lines 34-38) to protect the probe from damage (see col. 5, lines 36-38). The fact that the coating is insulative inherently requires that it comprises a suitable dielectric strength to protect the probe from damage by energy applied during the cardiac stimulation. Bilof does not disclose that this insulative coating is on the sheath. Vesley discloses a disposable, removable sheath of a flexible membrane material (see tracking data sheath 20, 20', 100; col. 2, lines 56-60 and 65-67). It would have been obvious to one of ordinary skill in the art at the time of the

Art Unit: 3766

invention to use Vesely's tracking data sheath instead of just a protective sheet because Vesely teaches that doing so allows for *quickly* and easily modifying an instrument to include tracking capabilities that are necessary to provide therapy in a specific location (see col. 2, lines 50-53). The examiner considers that slipping a sheath onto the probe is quicker than wrapping a protective sheet around it, similar to the difference between placing an object in a bag and gift wrapping it.

8. Regarding Claim 9, Bilof discloses at least one of the first and second conductors comprises a plurality of electrically connected conductors (see conducting members 36c-36f; col. 3, lines 40-50).

9. Regarding Claims 12 and 13, Bilof discloses that the cardiac stimulation comprises cardioversion, defibrillation or pacing in the atria and the ventricles of a subject (see col. 4, lines 37-39). The examiner considers that the heart H includes both atria and ventricles.

10. Regarding Claim 14, Bilof discloses that the cardiac stimulation comprises cardioversion, defibrillation or pacing of any of a plurality of pacemaker sites within a heart of a subject (see col. 3, lines 62-66 and col. 4, lines 53-59). The examiner considers that since the probe has multiple electrodes (see electrodes 22-32), a pair of electrodes is selected to carry out stimulation, and the electrodes are spaced apart from one another, then a plurality of sites must necessarily be stimulated.

11. Regarding Claim 16, Bilof discloses that the transthoracic pad is positioned over a thorax of a subject (see Figure 11).

12. Claim 6 is rejected under 35 U.S.C. 103(a) as being unpatentable over Bilof et al. (US Patent 5,191,885) and Vesely (US Patent 5,830,144) in view of Pless et al. (US Patent 4,640,298).

13. Regarding Claim 6, Bilof does not disclose an inflatable balloon. However, Pless discloses a similar esophageal probe that has an insulating sheath (see sheath 3; col. 5, line 43) further comprising an inflatable balloon (see either balloon 4Y or 4Z) positioned behind the conductor (see electrode material 5 in Figure 2) closing a gap between the esophagus and the sheath and pushing the conductor against a wall of the esophagus (see col. 4, lines 59-63). It would have been obvious to one of ordinary skill in the art at the time of the invention to incorporate Pless's inflatable balloon configuration in order to achieve the desired close contact between electrodes and the heart, thereby reducing current intensity and potential differences as taught by Pless (see col. 3, lines 12-16).

14. Claim 10 is rejected under 35 U.S.C. 103(a) as being unpatentable over Bilof et al. (US Patent 5,191,885) and Vesely (US Patent 5,830,144) in view of Crowley (US Patent 5,588,432).

15. Regarding Claim 10, Bilof discloses a disposable, removable protective sheet affixed to the endoscopic imaging probe (see sheet member 76; col. 5, lines 33-44). Bilof does not disclose a sheath. Vesely discloses a sheath, but does not explicitly disclose that it is acoustically transparent. Crowley teaches catheter construction using acoustically transparent conductors for the purpose of enabling sensing and stimulation of tissue while not obstructing the monitoring of the tissues acoustically. Thus, it would have been obvious to one of ordinary skill in the art at the time of the invention to have

Art Unit: 3766

used acoustically transparent conductors in the modified Bilof system in order to avoid compromised acoustically monitoring results that fail to disclose the impact of the acoustical testing on all the tissue in the test site (see col. 14, lines 31-36).

Conclusion

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Natasha N. Patel whose telephone number is 571-272-5818. The examiner can normally be reached on M-F 8:30-5:00.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Angela D. Sykes can be reached on 571-272-4955. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

Natasha N Patel
Patent Examiner
Art Unit 3766

/Kennedy J. Schaetzle/
Primary Examiner, AU 3766
August 5, 2007

